This is a working overview of visceral adipose tissue, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-17 and is reviewed periodically as new material appears.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
=== 25 June === The International Criminal Court issued arrest warrants against former Russian defence minister Sergei Shoigu and Chief of the General Staff Valery Gerasimov for war crimes and crimes against humanity pertaining to strikes on Ukrainian energy facilities from 2022 to 2023. The HUR claimed to have blown up a Russian ammunition depot in Voronezh Oblast. The governor of Belgorod Oblast claimed that one person was killed in a drone strike. Czech Prime Minister Petr Fiala said that the first batch of artillery ammunition purchased under the Czech-led initiative had been delivered to Ukraine. Russia and Ukraine conducted a prisoner exchange involving 90 POWs from each side. One of the prisoners swapped was a Ukrainian Orthodox priest who had been convicted and sentenced for “justifying Russian armed aggression“.
The laboratory industry is a part of the broader healthcare and health technology industry. Companies exist at various levels, including clinical laboratory services, suppliers of instrumentation equipment and consumable materials, and suppliers and developers of diagnostic tests themselves (often by biotechnology companies). Clinical laboratory services includes large multinational corporations such LabCorp, Quest Diagnostics, and Sonic Healthcare but a significant portion of revenue, estimated at 60% in the United States, is generated by hospital labs. In 2018, the total global revenue for these companies was estimated to reach $146 billion by 2024. Another estimate places the market size at $205 billion, reaching $333 billion by 2023. The American Association for Clinical Chemistry (AACC) represents professionals in the field. Clinical laboratories are supplied by other multinational companies which focus on materials and equipment, which can be used for both scientific research and medical testing. The largest of these is Thermo Fisher Scientific. In 2016, global life sciences instrumentation sales were around $47 billion, not including consumables, software, and services. In general, laboratory equipment includes lab centrifuges, transfection solutions, water purification systems, extraction techniques, gas generators, concentrators and evaporators, fume hoods, incubators, biological safety cabinets, bioreactors and fermenters, microwave-assisted chemistry, lab washers, and shakers and stirrers.
== Medical use == Silicone gel sheeting is the gold-standard and non-invasive treatment for hypertrophic and keloid scars. During skin injury repair, dermal cells proliferate and migrate from the skin tissue to the wound, producing collagen and causing contraction of the placement dermis. These scars are proliferative due to chronic inflammation and overproduction of abnormal collagen. Common clinical presentations of these scars are raised, thickened, red, or dark-colored. Patients may also experience pain and itching. Hypertrophic scars are elevated scars that remain in the region of the original lesion following mechanical traumas, burns, and necrotizing infections. These scars typically develop in locations under tension, such as shoulders, ankles, knees, and the neck. Hypertrophic scars are generally confined to the boundaries of the original wound and tend to diminish over time.
Sources: en.wikipedia.org
It is difficult or impossible to reliably evaluate whether an advanced AI is sentient (has the ability to feel), and if so, to what degree. But if there is a significant chance that a given machine can feel and suffer, then it may be entitled to certain rights or welfare protection measures, similarly to animals. Sapience (a set of capacities related to high intelligence, such as discernment or self-awareness) may provide another moral basis for AI rights. Robot rights are also sometimes proposed as a practical way to integrate autonomous agents into society. In 2017, the European Union considered granting "electronic personhood" to some of the most capable AI systems. Similarly to the legal status of companies, it would have conferred rights but also responsibilities. Critics argued in 2018 that granting rights to AI systems would downplay the importance of human rights, and that legislation should focus on user needs rather than speculative futuristic scenarios. They also noted that robots lacked the autonomy to take part in society on their own. Progress in AI increased interest in the topic. Proponents of AI welfare and rights often argue that AI sentience, if it emerges, would be particularly easy to deny. They warn that this may be a moral blind spot analogous to slavery or factory farming, which could lead to large-scale suffering if sentient AI is created and carelessly exploited.
== Publication history == Mogo first appeared in Green Lantern (vol. 2) #188 (May 1985) in a story titled "Mogo Doesn't Socialize" and was created by writer Alan Moore and artist Dave Gibbons. Although initially a one-off character from a short story, the planet has grown in importance in the Green Lantern mythos and is a necessary part of the process for distributing power rings as well as a destination for Corps members to recuperate.
=== Chemical reactions === Diallyl disulfide can be readily oxidized to allicin with hydrogen peroxide or peracetic acid. Allicin in turn can hydrolyze giving diallyl disulfide and trisulfide. Reaction of diallyl disulfide with liquid sulfur gives a mixture containing diallyl polysulfides with as many as 22 sulfur atoms in a continuous chain identified. When diallyl disulfide is heated it decomposes giving a complex mixture. The carbon-sulfur bond of diallyl disulfide is 16 kcal mol−1 weaker than the sulfur-sulfur bond (46 kcal mol−1 versus 62 kcal mol−1, respectively), with the consequence that on heating diallyl disulfide gives the allyldithio radical (AllSS•), which through addition to the double bonds in diallyl disulfide followed by fragmentation and subsequent reactions generates numerous organosulfur compounds, many of which are found in trace amounts in distilled garlic oil. In the presence of a catalyst, diallyl disulfide can combine with alkyl halides forming 1-alkylthio-3-allylthio-1-propene and 1,3-di(alkylthio)propene.
==== Resignation of Walter Ayala ==== On 4 November 2021, the General Commander of the Army, José Vizcarra Álvarez, and Jorge Luis Chaparro, the General Commander of the Air Force, were relieved from their duties. Both had served in their positions for 3 months prior to their removal. On 8 November 2021, Vizcarra claimed that President Castillo, Defense Minister Walter Ayala, and presidential secretary Bruno Pacheco had pressured him to irregularly promote two colonels. Vizcarra claimed that his refusal to promote them led to him being removed as General Commander of the Army. Subsequently, members from the Congressional opposition denounced the alleged irregularities. They began to prepare a motion of interpellation against the Defense Minister, which would allow Congress to question him on the incident. Jorge Montoya, the spokesperson of Popular Renewal, stated that following the interpellations he would impeach Ayala. Afterward, Ayala stated that he was evaluating resigning as Minister of Defense due to "continuous attacks." However, he denied claims that he had interfered with the promotions. Afterward, several other generals affirmed that the Secretary of the Presidency had interfered with promotions. Chaparro, the former commander of the Air force, claimed that he had been asked on 3 occasions to promote people who did not have the necessary skills. The leader of Free Peru, Vladimir Cerrón, distanced his party from the scandal, saying that Free Peru does not lead the current government.
Sources: en.wikipedia.org
=== Availability === Cyproheptadine is available widely throughout the world. This includes in Australia, Canada, Europe, Hong Kong, India, Japan, Mexico, Turkey, the United Kingdom, and the United States, among others.
== Awards and recognition == Eke has received several awards for his contributions to medicine and public health. These include the Donald F. Richardson Memorial Research Award from ACOG, the Kenneth Warren Prize from the Cochrane Collaboration, and the Young Physician-Scientist Award from the American Society for Clinical Investigation (ASCI). He is a member of both the Alpha Omega Alpha Honor Medical Society and the Delta Omega Honorary Society in Public Health. In 2024, he was recognized by the NIH Common Fund as a recipient of the Director's Pioneer Award, one of the agency's most competitive and prestigious awards for high-risk, high-reward research. In 2025, Eke was recognized as one of the top 1% of Gynecologic Surgery Research All-Stars. Eke's research and expert opinion have been featured in a range of media outlets, including STAT News, MedPage Today, Medscape, HuffPost, and Runner's World.
=== Telechelic oligomer approach === The telechelic oligomer approach applies the usual polymerization manner except that one includes a monofunctional reactant to stop reaction at the oligomer stage, generally in the 50–3000 molecular weight. The monofunctional reactant not only limits polymerization but end-caps the oligomer with functional groups capable of subsequent reaction to achieve curing of the oligomer. Functional groups like alkyne, norbornene, maleimide, nitrite, and cyanate have been used for this purpose. Maleimide and norbornene end-capped oligomers can be cured by heating. Alkyne, nitrile, and cyanate end-capped oligomers can undergo cyclotrimerization, yielding aromatic structures.
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.